Cannabis, Cannabinoids, and the Association with Psychosis

The Effects of Drug Abuse on the Human Nervous System

Volumn , Issue , 2013, Pages 423-474

  Radhakrishnan, Rajiv ^a,c   Addy, Peter H ^a   Sewell, R Andrew ^a,b,c   Skosnik, Patrick D ^a,b,c   Ranganathan, Mohini ^a,b,c   D'Souza, Deepak Cyril ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Yale University School of Medicine   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabis; Drug Abuse; Marijuana; Psychosis; Schizophrenia; Substance Abuse

Indexed keywords

EID: 84890183110     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-418679-8.00014-9     Document Type: Chapter

References (388)

1. AAPCC Synthetic Marijuana 2011, Data Updated December 12, 2011.
2. Adamec C., Pihl R.O., Leiter L. An analysis of the subjective marijuana experience. Int. J. Addict. 1976, 11:295-307.
3. Addington J., Addington D. Effect of substance misuse in early psychosis. Br. J. Psychiatry Suppl. 1998, 172:134-136.
4. Addington J., Duchak V. Reasons for substance use in schizophrenia. Acta Psychiatr. Scand. 1997, 96:329-333.
5. Aguado T., Palazuelos J., Monory K., Stella N., Cravatt B., Lutz B., Marsicano G., Kokaia Z., Guzman M., Galve-Roperh I. The endocannabinoid system promotes astroglial differentiation by acting on neural progenitor cells. J. Neurosci. 2006, 26:1551-1561.
6. Ajdacic-Gross V., Lauber C., Warnke I., Haker H., Murray R.M., Rossler W. Changing incidence of psychotic disorders among the young in Zurich. Schizophr. Res. 2007, 95:9-18.
7. Allebeck P., Adamsson C., Engstrom A., Rydberg U. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr. Scand. 1993, 88:21-24.
8. Allebeck P., Adamsson C., Engstrom A., Rydberg U. Cannabis and schizophrenia: a longitudinal study of cases treated in Stockholm County. Acta Psychiatr. Scand. 1993, 88:21-24. (erratum appears in Acta Psychiatr Scand 1993 Oct; 88(4):304).
9. Ames F. A clinical and metabolic study of acute intoxication with Cannabis sativa and its role in the model psychoses. J. Ment. Sci. 1958, 104:972-999.
10. Andreasen N.C., Nopoulos P., O'Leary D.S., Miller D.D., Wassink T., Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol. Psychiatry 1999, 46:908-920.
11. Andreasson S., Allebeck P., Engstrom A., Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2:1483-1486.
12. Andreasson S., Allebeck P., Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr. Scand. 1989, 79:505-510.
13. Arndt S., Tyrrell G., Flaum M., Andreasen N. Comorbidity of substance abuse and schizophrenia: the role of pre-morbid adjustment. Psychol. Med. 1992, 22:379-388.
14. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325:1212-1213.
15. Atwood B.K., Huffman J., Straiker A., Mackie K. JWH018, a common constituent of 'Spice' herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br. J. Pharmacol. 2010, 160:585-593.
16. Atwood B.K., Lee D., Straiker A., Widlanski T.S., Mackie K. CP47, 497-C8 and JWH073, commonly found in 'Spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur. J. Pharmacol. 2011, 659:139-145.
17. Aust R., Sharp C., Goulden C. Prevalence of Drug Use: Key Findings from the 2001/2002 British Crime Survey, Findings 182 2002, Home Office Research, Development and Statistics Directorate, London.
18. Auwarter V., Dresen S., Weinmann W., Muller M., Putz M., Ferreiros N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?. J. Mass Spectrom. 2009, 44:832-837.
19. Baeza I., Graell M., Moreno D., Castro-Fornieles J., Parellada M., Gonzalez-Pinto A., Paya B., Soutullo C., de la Serna E., Arango C. Cannabis use in children and adolescents with first episode psychosis: influence on psychopathology and short-term outcome (CAFEPS study). Schizophr. Res. 2009, 113:129-137.
20. Baigent M., Holme G., Hafner R.J. Self reports of the interaction between substance abuse and schizophrenia. Aust. N. Z. J. Psychiatry 1995, 29:69-74.
21. Baker A., Lewin T., Reichler H., Clancy R., Carr V., Garrett R., Sly K., Devir H., Terry M. Motivational interviewing among psychiatric in-patients with substance use disorders. Acta Psychiatr. Scand. 2002, 106:233-240.
22. Bangalore S.S., Prasad K.M., Montrose D.M., Goradia D.D., Diwadkar V.A., Keshavan M.S. Cannabis use and brain structural alterations in first episode schizophrenia-a region of interest, voxel based morphometric study. Schizophr. Res. 2008, 99:1-6.
23. Barkus E.J., Stirling J., Hopkins R.S., Lewis S. Cannabis-induced psychosis-like experiences are associated with high schizotypy. Psychopathology 2006, 39:175-178.
24. Benford D.M., Caplan J.P. Psychiatric sequelae of spice, K2, and synthetic cannabinoid receptor agonists. Psychosomatics 2011, 52:295.
25. Berghuis P., Dobszay M.B., Wang X., Spano S., Ledda F., Sousa K.M., Schulte G., Ernfors P., Mackie K., Paratcha G., Hurd Y.L., Harkany T. Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc. Natl. Acad. Sci. U.S.A 2005, 102:19115-19120.
26. Berghuis P., Rajnicek A.M., Morozov Y.M., Ross R.A., Mulder J., Urban G.M., Monory K., Marsicano G., Matteoli M., Canty A., Irving A.J., Katona I., Yanagawa Y., Rakic P., Lutz B., Mackie K., Harkany T. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 2007, 316:1212-1216.
27. Bersani G., Orlandi V., Kotzalidis G., Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur. Arch. Psychiatry Clin. Neurosci. 2002, 252:86-92.
28. Bhattacharyya S., Morrison P.D., Fusar-Poli P., Martin-Santos R., Borgwardt S., Winton-Brown T., Nosarti C., CM O.C., Seal M., Allen P., Mehta M.A., Stone J.M., Tunstall N., Giampietro V., Kapur S., Murray R.M., Zuardi A.W., Crippa J.A., Atakan Z., McGuire P.K. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 2010, 35:764-774.
29. Block R.I., O'Leary D.S., Ehrhardt J.C., Augustinack J.C., Ghoneim M.M., Arndt S., Hall J.A. Effects of frequent marijuana use on brain tissue volume and composition. Neuroreport 2000, 11:491-496.
30. Bolla K.I., Brown K., Eldreth D., Tate K., Cadet J.L. Dose-related neurocognitive effects of marijuana use. Neurology 2002, 59:1337-1343.
31. Boutros N.N., Belger A., Campbell D., D'Souza C., Krystal J. Comparison of four components of sensory gating in schizophrenia and normal subjects: a preliminary report. Psychiatry Res. 1999, 88:119-130.
32. Braff D.L. Information processing and attention dysfunctions in schizophrenia. Schizophr. Bull. 1993, 19:233-259.
33. Braff D.L., Light G.A. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl.) 2004, 174:75-85.
34. Bramon E., Rabe-Hesketh S., Sham P., Murray R.M., Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophr. Res. 2004, 70:315-329.
35. Bramon E., McDonald C., Croft R.J., Landau S., Filbey F., Gruzelier J.H., Sham P.C., Frangou S., Murray R.M. Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. NeuroImage 2005, 27:960-968.
36. Brandt J. The hopkins verbal learning test: development of a new memory test with six equivalent forms. Clin. Neuropsychol. 1991, 5:125-142.
37. Brook M. Psychosis after cannabis abuse. BMJ 1984, 288:1381. (Clinical research ed.).
38. Brunette M.F., Mueser K.T., Xie H., Drake R.E. Relationships between symptoms of schizophrenia and substance abuse. J. Nerv. Ment. Dis. 1997, 185:13-20.
39. Buhler B., Hambrecht M., Loffler W., Van der Heiden W., Hafner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res. 2002, 54:243-251.
40. The Big Business of Synthetic Highs (Bloomberg Businessweek) 2011, Businessweek, B.
41. Butovsky E., Juknat A., Goncharov I., Elbaz J., Eilam R., Zangen A., Vogel Z. In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to delta-tetrahydrocannabinol. J. Neurochem. 2005, 93:802-811.
42. Cadenhead K.S., Light G.A., Geyer M.A., Braff D.L. Sensory gating deficits assessed by the P50 event-related potential in subjects with schizotypal personality disorder. Am. J. Psychiatry 2000, 157:55-59.
43. Cahn W., Hulshoff Pol H.E., Caspers E., van Haren N.E., Schnack H.G., Kahn R.S. Cannabis and brain morphology in recent-onset schizophrenia. Schizophr. Res. 2004, 67:305-307.
44. Campbell A.M., Evans M., Thomson J.L., Williams M.J. Cerebral atrophy in young cannabis smokers. Lancet 1971, 2:1219-1224.
45. Carroll C.A., O'Donnell B.F., Shekhar A., Hetrick W.P. Timing dysfunctions in schizophrenia span from millisecond to several-second durations. Brain Cogn. 2009, 70:181-190.
46. CBS Synthetic Marijuana: How Dangerous Is It? 2011, (CBS Miami).
47. Cha Y.M., White A.M., Kuhn C.M., Wilson W.A., Swartzwelder H.S. Differential effects of delta9-THC on learning in adolescent and adult rats. Pharmacol. Biochem. Behav. 2006, 83:448-455.
48. Chan G.C., Hinds T.R., Impey S., Storm D.R. Hippocampal neurotoxicity of delta9-tetrahydrocannabinol. J. Neurosci. 1998, 18:5322-5332.
49. Chopra G.S., Smith J.W. Psychotic reactions following cannabis use in East Indians. Arch. Gen. Psychiatry 1974, 30:24-27.
50. Citron M.L., Herman T.S., Vreeland F., Krasnow S.H., Fossieck B.E., Harwood S., Franklin R., Cohen M.H. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat Rep. 1985, 69:109-112.
51. Cleghorn J.M., Kaplan R.D., Szechtman B., Szechtman H., Brown G.M., Franco S. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J. Clin. Psychiatry 1991, 52:26-30.
52. CNN Synthetic marijuana a growing trend among teens, authorities say (CNN) 2011.
53. Co B.T., Goodwin D.W., Gado M., Mikhael M., Hill S.Y. Absence of cerebral atrophy in chronic cannabis users. Evaluation by computerized transaxial tomography. JAMA 1977, 237:1229-1230.
54. Cohen J., Morrison S., Greenberg J., Saidinejad M. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 2012.
55. Collip D., Myin-Germeys I., Van Os J. Does the concept of "sensitization" provide a plausible mechanism for the putative link between the environment and schizophrenia?. Schizophr. Bull. 2008, 34:220-225.
56. Compton W.M., Grant B.F., Colliver J.D., Glantz M.D., Stinson F.S. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA 2004, 291:2114-2121.
57. Conrad D.G., Elsmore T.F., Sodetz F.J. 9-tetrahydrocannabinol: dose-related effects on timing behavior in chimpanzee. Science 1972, 175:547-550. New York, N.Y.
58. Corkin S., Milner B., Rasmussen T. Effects of different cortical excisions on sensory thresholds in man. Trans. Am. Neurol. Assoc. 1964, 89:112-116.
59. Cousijn J., Wiers R.W., Ridderinkhof K.R., van den Brink W., Veltman D.J., Goudriaan A.E. Grey matter alterations associated with cannabis use: results of a VBM study in heavy cannabis users and healthy controls. NeuroImage 2012, 59:3845-3851.
60. Crean R.D., Crane N.A., Mason B.J. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J. Addict. Med. 2011, 5:1-8.
61. Crews F., He J., Hodge C. Adolescent cortical development: a critical period of vulnerability for addiction. Pharmacol. Biochem. Behav. 2007, 86:189-199.
62. Cronin C.M., Sallan S.E., Gelber R., Lucas V.S., Laszlo J. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J. Clin. Pharmacol. 1981, 21:43S-50S.
63. Cuffel B., Heithoff K., Lawson W. Correlates of patterns of substance abuse among patients with schizophrenia. Hosp. Community Psychiatry 1993, 44:247-251.
64. D'Souza D.C. Cannabinoids and psychosis. Int. Rev. Neurobiol. 2007, 78:289-326.
65. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., Braley G., Gueorguieva R., Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572.
66. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 2005, 57:594-608.
67. D'Souza D.C., Pittman B., Perry E., Simen A. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology (Berl.) 2008.
68. D'Souza D.C., Ranganathan M., Braley G., Gueorguieva R., Zimolo Z., Cooper T., Perry E., Krystal J. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008, 33:2505-2516.
69. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:413-431.
70. D'Souza D.C., Fridberg D.J., Skosnik P.D., Williams A., Roach B., Singh N., Carbuto M., Elander J., Schnakenberg A., Pittman B., Sewell R.A., Ranganathan M., Mathalon D. Dose-related modulation of event-related potentials to novel and target stimuli by intravenous delta(9)-THC in humans. Neuropsychopharmacology 2012.
71. Dargan P.I., Hudson S., Ramsey J., Wood D.M. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in 'Spice'. Int. J. Drug Policy 2011, 22:274-277.
72. Davalos D.B., Kisley M.A., Ross R.G. Effects of interval duration on temporal processing in schizophrenia. Brain Cogn. 2003, 52:295-301.
73. de Sola S., Tarancon T., Pena-Casanova J., Espadaler J.M., Langohr K., Poudevida S., Farre M., Verdejo-Garcia A., de la Torre R. Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study. Psychopharmacology (Berl.) 2008, 200:425-437.
74. de Wilde O.M., Bour L.J., Dingemans P.M., Koelman J.H., Linszen D.H. A meta-analysis of P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. Schizophr. Res. 2007, 97:137-151.
75. Dekker, N., Schmitz, N., Peters, B.D., van Amelsvoort, T.A., Linszen, D.H., de Haan, L. Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res. 181, 51-56.
76. Dekker N., Linszen D., De Haan L. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology 2009, 42:350-360.
77. Der G., Gupta S., Murray R.M. Is schizophrenia disappearing?. Lancet 1990, 335:513-516.
78. Derkinderen P., Valjent E., Toutant M., Corvol J.C., Enslen H., Ledent C., Trzaskos J., Caboche J., Girault J.A. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci. 2003, 23:2371-2382.
79. DeRosse P., Kaplan A., Burdick K.E., Lencz T., Malhotra A.K. Cannabis use disorders in schizophrenia: effects on cognition and symptoms. Schizophr. Res. 2010, 120:95-100.
80. Diasio R.B., Ettinger D.S., Satterwhite B.E. Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations. J. Clin. Pharmacol. 1981, 21:81S-85S.
81. Dissanayake D.W., Zachariou M., Marsden C.A., Mason R. Auditory gating in rat hippocampus and medial prefrontal cortex: effect of the cannabinoid agonist WIN55,212-2. Neuropharmacology 2008, 55:1397-1404.
82. Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 1999, 35(Suppl.):S93-100.
83. Dixon L., Haas G., Weiden P., Sweeney J., Frances A. Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports. Schizophr. Bull. 1990, 16:69-79.
84. Dixon L., Haas G., Weiden P.J., Sweeney J., Frances A.J. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry 1991, 148:224-230.
85. Downer E.J., Gowran A., Campbell V.A. A comparison of the apoptotic effect of delta(9)-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Res. 2007, 1175:39-47.
86. Dresen S., Ferreiros N., Putz M., Westphal F., Zimmermann R., Auwarter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J. Mass Spectrom. 2010, 45:1186-1194.
87. Duncan C.C. Event-related brain potentials: a window on information processing in schizophrenia. Schizophr. Bull. 1988, 14:199-203.
88. Edwards C.R., Skosnik P.D., Steinmetz A.B., Vollmer J.M., O'Donnell B.F., Hetrick W.P. Assessment of forebrain-dependent trace eyeblink conditioning in chronic cannabis users. Neurosci. Lett. 2008, 439:264-268.
89. Edwards C.R., Skosnik P.D., Steinmetz A.B., O'Donnell B.F., Hetrick W.P. Sensory gating impairments in heavy cannabis users are associated with altered neural oscillations. Behav. Neurosci. 2009, 123:894-904.
90. Eggan S.M., Lewis D.A. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb. Cortex 2007, 17:175-191.
91. Ehrenreich H., Rinn T., Kunert H.J., Moeller M.R., Poser W., Schilling L., Gigerenzer G., Hoehe M.R. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl.) 1999, 142:295-301.
92. Emrich H.M., Weber M.M., Wendl A., Zihl J., von Meyer L., Hanisch W. Reduced binocular depth inversion as an indicator of cannabis-induced censorship impairment. Pharmacol. Biochem. Behav. 1991, 40:689-690.
93. Every-Palmer S. Warning: legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addiction 2010, 105:1859-1860.
94. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend. 2011, 117:152-157.
95. Farrell M., Howes S., Taylor C., Lewis G., Jenkins R., Bebbington P., Jarvis M., Brugha T., Gill B., Meltzer H. Substance misuse and psychiatric comorbidity: an overview of the OPCS national psychiatric morbidity survey. Addict. Behav. 1998, 23:909-918.
96. Ferdinand R.F., Sondeijker F., van der Ende J., Selten J.P., Huizink A., Verhulst F.C. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005, 100:612-618.
97. Fergusson D.M., Horwood L.J., Ridder E.M. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005, 100:354-366.
98. Fernandez-Ruiz J., Berrendero F., Hernandez M.L., Ramos J.A. The endogenous cannabinoid system and brain development. Trends Neurosci. 2000, 23:14-20.
99. Fontes M.A., Bolla K.I., Cunha P.J., Almeida P.P., Jungerman F., Laranjeira R.R., Bressan R.A., Lacerda A.L. Cannabis use before age 15 and subsequent executive functioning. Br. J. Psychiatry 2011, 198:442-447.
100. Fowler I., Carr V., Carter N., Lewin T. Patterns of current and lifetime substance use in schizophrenia. Schizophr. Bull. 1998, 24:443-455.
101. Frank M.J., Moustafa A.A., Haughey H.M., Curran T., Hutchison K.E. Genetic triple dissociation reveals multiple roles for dopamine in reinforcement learning. Proc. Natl. Acad. Sci. U.S.A 2007, 104:16311-16316.
102. Fried P.A. Marihuana use by pregnant women and effects on offspring: an update. Neurobehav. Toxicol. Teratol. 1982, 4:451-454.
103. Fried P.A., Makin J.E. Neonatal behavioural correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. Neurotoxicol. Teratol. 1987, 9:1-7.
104. Fried P.A., O'Connell C.M. A comparison of the effects of prenatal exposure to tobacco, alcohol, cannabis and caffeine on birth size and subsequent growth. Neurotoxicol. Teratol. 1987, 9:79-85.
105. Fried P.A., Watkinson B., Gray R. Differential effects on cognitive functioning in 9- to 12-year olds prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol. 1998, 20:293-306.
106. Fried P.A., Watkinson B., Gray R. Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol. 2003, 25:427-436.
107. Fried P.A., Watkinson B., Gray R. Neurocognitive consequences of marihuana-a comparison with pre-drug performance. Neurotoxicol. Teratol. 2005, 27:231-239.
108. Fusar-Poli P., Crippa J.A., Bhattacharyya S., Borgwardt S.J., Allen P., Martin-Santos R., Seal M., Surguladze S.A., O'Carrol C., Atakan Z., Zuardi A.W., McGuire P.K. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry 2009, 66:95-105.
109. Galve-Roperh I., Aguado T., Palazuelos J., Guzman M. The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 2007, 13:109-114.
110. Galve-Roperh I., Palazuelos J., Aguado T., Guzman M. The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:371-382.
111. Garcia-Gil L., Romero J., Ramos J.A., Fernandez-Ruiz J.J. Cannabinoid receptor binding and mRNA levels in several brain regions of adult male and female rats perinatally exposed to delta9-tetrahydrocannabinol. Drug Alcohol Depend. 1999, 55:127-136.
112. Gearon J.S., Bellack A.S., Rachbeisel J., Dixon L. Drug-use behavior and correlates in people with schizophrenia. Addict. Behav. 2001, 26:51-61.
113. Ginsburg B.C., McMahon L.R., Sanchez J.J., Javors M.A. Purity of synthetic cannabinoids sold online for recreational use. J. Anal. Toxicol. 2012, 36:66-68.
114. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., Cassano T., Morgese M.G., Debonnel G., Duranti A., Tontini A., Tarzia G., Mor M., Trezza V., Goldberg S.R., Cuomo V., Piomelli D. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. U.S.A 2005, 102:18620-18625.
115. Goldschmidt L., Day N.L., Richardson G.A. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol. Teratol. 2000, 22:325-336.
116. Goldschmidt L., Richardson G.A., Willford J., Day N.L. Prenatal marijuana exposure and intelligence test performance at age 6. J. Am. Acad. Child Adolesc. Psychiatry 2008, 47:254-263.
117. Gordon M. Microprocessor-based assessment of attention deficit disorders (ADD). Psychopharmacol. Bull. 1986, 22:288-290.
118. Goswami S., Mattoo S.K., Basu D., Singh G. Substance-abusing schizophrenics: do they self-medicate?. Am. J. Addict. 2004, 13:139-150.
119. Green B., Kavanagh D., Young R. Being stoned: a review of self-reported cannabis effects. Drug Alcohol Rev. 2003, 22:453-460.
120. Green A.I., Tohen M.F., Hamer R.M., Strakowski S.M., Lieberman J.A., Glick I., Clark W.S. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 2004, 66:125-135.
121. Green A.I., Tohen M.F., Hamer R.M., Strakowski S.M., Lieberman J.A., Glick I., Clark W.S., Group H.R. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.[see comment]. Schizophr. Res. 2004, 66:125-135.
122. Green B., Kavanagh D.J., Young R.M. Reasons for cannabis use in men with and without psychosis. Drug Alcohol Rev. 2004, 23:445-453.
123. Green B., Young R., Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br. J. Psychiatry 2005, 187:306-313.
124. Gregg L., Barrowclough C., Haddock G. Development and validation of a scale for assessing reasons for substance use in schizophrenia: the ReSUS scale. Addict. Behav. 2009, 34:830-837.
125. Grossman W. Adverse reactions associated with cannabis products in India. Ann. Intern. Med. 1969, 70:529-533.
126. GROUP G.R.a.O.i.P.I. Evidence that familial liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. Arch. Gen. Psychiatry 2011, 68:138-147.
127. Grunwald T., Boutros N.N., Pezer N., von Oertzen J., Fernandez G., Schaller C., Elger C.E. Neuronal substrates of sensory gating within the human brain. Biol. Psychiatry 2003, 53:511-519.
128. Halikas J., Weller R., Morse C. Effects of regular marijuana use on sexual performance. J. Psychoactive Drugs 1982, 14:59-70.
129. Hall W., Pacula R. Cannabis Use and Dependence: Public Health and Public Policy 2003, Cambridge University Press, London.
130. Hall W., Solowij N. Adverse effects of cannabis. Lancet 1998, 352:1611-1616.
131. Hambrecht M., Hafner H. Substance abuse and the onset of schizophrenia. Biol. Psychiatry 1996, 40:1155-1163.
132. Hambrecht M., Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust. N. Z. J. Psychiatry 2000, 34:468-475.
133. Han C.J., Robinson J.K. Cannabinoid modulation of time estimation in the rat. Behav. Neurosci. 2001, 115:243-246.
134. Hannerz J., Hindmarsh T. Neurological and neuroradiological examination of chronic cannabis smokers. Ann. Neurol. 1983, 13:207-210.
135. Harkany T., Guzman M., Galve-Roperh I., Berghuis P., Devi L.A., Mackie K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol. Sci. 2007, 28:83-92.
136. Harley M., Kelleher I., Clarke M., Lynch F., Arseneault L., Connor D., Fitzpatrick C., Cannon M. Cannabis use and childhood trauma interact additively to increase the risk of psychotic symptoms in adolescence. Psychol. Med. 2010, 40:1627-1634.
137. Harper J.W., Heath R.G., Myers W.A. Effects of Cannabis sativa on ultrastructure of the synapse in monkey brain. J. Neurosci. Res. 1977, 3:87-93.
138. Hart C.L., van Gorp W., Haney M., Foltin R.W., Fischman M.W. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 2001, 25:757-765.
139. Heath R.G., Fitzjarrell A.T., Fontana C.J., Garey R.E. Cannabis sativa: effects on brain function and ultrastructure in rhesus monkeys. Biol. Psychiatry 1980, 15:657-690.
140. Heim M.E., Romer W., Queisser W. Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting. J. Clin. Pharmacol. 1981, 21:86S-89S.
141. Heim M.E., Queisser W., Altenburg H.P. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. Cancer Chemother. Pharmacol. 1984, 13:123-125.
142. Heinrichs R.W. Meta-analysis and the science of schizophrenia: variant evidence or evidence of variants?. Neurosci. Biobehav. Rev. 2004, 28:379-394.
143. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
144. Heishman S.J., Huestis M.A., Henningfield J.E., Cone E.J. Acute and residual effects of marijuana: profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacol. Biochem. Behav. 1990, 37:561-565.
145. Hekimian L.J., Gershon S. Characteristics of drug abusers admitted to a psychiatric hospital. JAMA 1968, 205:125-130.
146. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005, 330:11.
147. Henquet C., Murray R., Linszen D., van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 2005, 31:608-612.
148. Henquet C., Rosa A., Krabbendam L., Papiol S., Fananas L., Drukker M., Ramaekers J.G., van Os J. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006, 31:2748-2757.
149. Hickman M., Vickerman P., Macleod J., Kirkbride J., Jones P.B. Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and Wales. Addiction 2007, 102:597-606.
150. Hicks R.E., Gualtieri C.T., Mayo J.P., Perez-Reyes M. Cannabis, atropine, and temporal information processing. Neuropsychobiology 1984, 12:229-237.
151. Hillyard S.A., Hink R.F., Schwent V.L., Picton T.W. Electrical signs of selective attention in the human brain. Science 1973, 182:177-180.
152. Hooker W.D., Jones R.T. Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication. Psychopharmacology 1987, 91:20-24.
153. Houston J.E., Murphy J., Adamson G., Stringer M., Shevlin M. Childhood sexual abuse, early cannabis use, and psychosis: testing an interaction model based on the national comorbidity survey. Schizophr. Bull. 2008, 34:580-585.
154. Hu X., Primack B.A., Barnett T.E., Cook R.L. College students and use of K2: an emerging drug of abuse in young persons. Subst. Abuse Treat. Prev. Policy 2011, 6:16.
155. Huffman J.W., Padgett L.W. Recent developments in the medicinal chemistry of cannabimimetic indoles, pyrroles and indenes. Curr. Med. Chem. 2005, 12:1395-1411.
156. Huffman J.W., Zengin G., Wu M.J., Lu J., Hynd G., Bushell K., Thompson A.L., Bushell S., Tartal C., Hurst D.P., Reggio P.H., Selley D.E., Cassidy M.P., Wiley J.L., Martin B.R. Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. Bioorg. Med. Chem. 2005, 13:89-112.
157. Hurst D., Loeffler G., McLay R. Psychosis associated with synthetic cannabinoid agonists: a case series. Am. J. Psychiatry 2011, 168:1119.
158. Ilan A.B., Gevins A., Coleman M., Elsohly M.A., de Wit H. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav. Pharmacol. 2005, 16:487-496.
159. Isbell H., Jasinski D.R. A comparison of LSD-25 with (-)-delta-9-trans-tetrahydrocannabinol (THC) and attempted cross tolerance between LSD and THC. Psychopharmacologia 1969, 14:115-123.
160. Isbell H., Gorodetzsky C.W., Jasinski D., Claussen U., von Spulak F., Korte F. Effects of (-)delta-9-trans-tetrahydrocannabinol in man. Psychopharmacologia 1967, 11:184-188.
161. Jablensky A., McGrath J., Herrman H., Castle D., Gureje O., Evans M., Carr V., Morgan V., Korten A., Harvey C. Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Aust. N. Z. J. Psychiatry 2000, 34:221-236.
162. Jager G., Kahn R.S., Van Den Brink W., Van Ree J.M., Ramsey N.F. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. Psychopharmacology 2006, 185:358-368.
163. Jager G., Van Hell H.H., De Win M.M., Kahn R.S., Van Den Brink W., Van Ree J.M., Ramsey N.F. Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur. Neuropsychopharmacol. 2007, 17:289-297.
164. Jain A.K., Ryan J.R., McMahon F.G., Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J. Clin. Pharmacol. 1981, 21:320S-326S.
165. James A., Hough M., James S., Winmill L., Burge L., Nijhawan S., Matthews P.M., Zarei M. Greater white and grey matter changes associated with early cannabis use in adolescent-onset schizophrenia (AOS). Schizophr. Res. 2011, 128:91-97.
166. Jeon Y.W., Polich J. Meta-analysis of P300 and schizophrenia: patients, paradigms, and practical implications. Psychophysiology 2003, 40:684-701.
167. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J. Clin. Invest. 2005, 115:3104-3116.
168. Jin K., Xie L., Kim S.H., Parmentier-Batteur S., Sun Y., Mao X.O., Childs J., Greenberg D.A. Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol. Pharmacol. 2004, 66:204-208.
169. Johns A. Psychiatric effects of cannabis. Br. J. Psychiatry 2001, 178:116-122.
170. Johnson B.A. Psychopharmacological effects of cannabis. Br. J. Hosp. Med. 1990, 43(122). 114-6-118-20.
171. Johnson B.A., Smith B.L., Taylor P. Cannabis and schizophrenia. Lancet 1988, 1:592-593.
172. Jones R.T., Stone G.C. Psychological studies of marijuana and alcohol in man. Psychopharmacologia 1970, 18:108-117.
173. Joyal C.C., Halle P., Lapierre D., Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr. Res. 2003, 63:297-299.
174. Juckel G., Roser P., Nadulski T., Stadelmann A.M., Gallinat J. Acute effects of delta-9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. Schizophr. Res. 2007, 97:109-117.
175. Jutras-Aswad D., DiNieri J.A., Harkany T., Hurd Y.L. Neurobiological consequences of maternal cannabis on human fetal development and its neuropsychiatric outcome. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:395-412.
176. Kaufmann R.M., Kraft B., Frey R., Winkler D., Weiszenbichler S., Backer C., Kasper S., Kress H.G. Acute psychotropic effects of oral cannabis extract with a defined content of delta-9-tetrahydrocannabinol (THC) in healthy volunteers. Pharmacopsychiatry 2010, 43:24-32.
177. Kay S.R., Opler L.A., Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. Br. J. Psychiatry 1986, 149:439-448.
178. Keeler M.H., Moore E. Paranoid reactions while using marijuana. Dis. Nerv. Syst. 1974, 35:535-536.
179. Kempel P., Lampe K., Parnefjord R., Hennig J., Kunert H.J. Auditory-evoked potentials and selective attention: different ways of information processing in cannabis users and controls. Neuropsychobiology 2003, 48:95-101.
180. Kenny J.B., Wilkinson P.M. Levonantradol effectiveness in cancer patients resistant to conventional anti-emetics. Clin. Oncol. 1982, 8:335-339.
181. Kessler R., Foster C., Saunders W., Stang P. Social consequences of psychiatric disorders, I: educational attainment. Am. J. Psychiatry 1995, 152:1026-1032.
182. Kiehl K.A., Laurens K.R., Duty T.L., Forster B.B., Liddle P.F. Neural sources involved in auditory target detection and novelty processing: an event-related fMRI study. Psychophysiology 2001, 38:133-142.
183. Kikura-Hanajiri R., Uchiyama N., Goda Y. Survey of current trends in the abuse of psychotropic substances and plants in Japan. Leg. Med. (Tokyo) 2011, 13:109-115.
184. Kivlahan D.R., Heiman J.R., Wright R.C., Mundt J.W., Shupe J.A. Treatment cost and rehospitalization rate in schizophrenic outpatients with a history of substance abuse. Hosp. Community Psychiatry 1991, 42:609-614.
185. Knudsen P., Vilmar T. Cannabis and neuroleptic agents in schizophrenia. Acta Psychiatr. Scand. 1984, 69:162-174.
186. Koethe D., Gerth C.W., Neatby M.A., Haensel A., Thies M., Schneider U., Emrich H.M., Klosterkotter J., Schultze-Lutter F., Leweke F.M. Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr. Res. 2006, 88:142-150.
187. Kolansky H., Moore W.T. Effects of marihuana on adolescents and young adults. J Psychiatr. Nurs. Ment. Health Serv. 1971, 9:9-16.
188. Konings M., Stefanis N., Kuepper R., de Graaf R., ten Have M., van Os J., Bakoula C., Henquet C. Replication in two independent population-based samples that childhood maltreatment and cannabis use synergistically impact on psychosis risk. Psychol. Med. 2012, 42:149-159.
189. Koskinen J., Lohonen J., Koponen H., Isohanni M., Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr. Bull 2009.
190. Kuehnle J., Mendelson J.H., Davis K.R., New P.F. Computed tomographic examination of heavy marijuana smokers. JAMA 1977, 237:1231-1232.
191. Kuepper R., Henquet C., Lieb R., Wittchen H.U., van Os J. Non-replication of interaction between cannabis use and trauma in predicting psychosis. Schizophr. Res. 2011, 131:262-263.
192. Kuepper R., van Os J., Lieb R., Wittchen H.U., Hofler M., Henquet C. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011, 342:d738.
193. Kumra S., Robinson P., Tambyraja R., Jensen D., Schimunek C., Houri A., Reis T., Lim K. Parietal lobe volume deficits in adolescents with schizophrenia and adolescents with cannabis use disorders. J. Am. Acad. Child Adolesc. Psychiatry 2012, 51:171-180.
194. Landfield P.W., Cadwallader L.B., Vinsant S. Quantitative changes in hippocampal structure following long-term exposure to delta 9-tetrahydrocannabinol: possible mediation by glucocorticoid systems. Brain Res. 1988, 443:47-62.
195. Lapoint J., James L.P., Moran C.L., Nelson L.S., Hoffman R.S., Moran J.H. Severe toxicity following synthetic cannabinoid ingestion. Clin. Toxicol. 2011, 49:760-764.
196. Laszlo J., Lucas V.S., Hanson D.C., Cronin C.M., Sallan S.E. Levonantradol for chemotherapy-induced emesis: phase I-II oral administration. J. Clin. Pharmacol. 1981, 21:51S-56S.
197. Lawston J., Borella A., Robinson J.K., Whitaker-Azmitia P.M. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Res. 2000, 877:407-410.
198. Leweke M., Kampmann C., Radwan M., Dietrich D.E., Johannes S., Emrich H.M., Munte T.F. The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials. Neuropsychobiology 1998, 37:104-111.
199. Leweke F.M., Schneider U., Thies M., Munte T.F., Emrich H.M. Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology (Berl.) 1999, 142:230-235.
200. Leweke F.M., Schneider U., Radwan M., Schmidt E., Emrich H.M. Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol. Biochem. Behav. 2000, 66:175-181.
201. Lichtman A.H., Varvel S.A., Martin B.R. Endocannabinoids in cognition and dependence. Prostaglandins Leukot. Essent. Fatty Acids 2002, 66:269-285.
202. Lindemann E., Malamud W. Experimental analysis of the psychopathological effects of intoxicating drug. Am. J. Psychiatry 1934, 90:853-881.
203. Lindigkeit R., Boehme A., Eiserloh I., Luebbecke M., Wiggermann M., Ernst L., Beuerle T. Spice: a never ending story?. Forensic Sci. Int. 2009, 191:58-63.
204. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry 1994, 51:273-279.
205. Løberg E.M., Hugdahl K. Cannabis use and cognition in schizophrenia. Front. Hum. Neurosci. 2009, 3:53.
206. Luck S.J., Mathalon D.H., O'Donnell B.F., Hamalainen M.S., Spencer K.M., Javitt D.C., Uhlhaas P.J. A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol. Psychiatry 2010.
207. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol. Biochem. Behav. 2005, 81:319-330.
208. Luntz-Leybman V., Bickford P.C., Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Res. 1992, 587:130-136.
209. Lyons M.J., Bar J.L., Panizzon M.S., Toomey R., Eisen S., Xian H., Tsuang M.T. Neuropsychological consequences of regular marijuana use: a twin study. Psychol. Med. 2004, 34:1239-1250.
210. Løberg E.M., Hugdahl K. Cannabis use and cognition in schizophrenia. Front. Hum. Neurosci. 2009, 3:53.
211. Machado Rocha F.C., Stefano S.C., De Cassia Haiek R., Rosa Oliveira L.M., Da Silveira D.X. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur. J. Cancer Care 2008, 17:431-443.
212. Macleod J. Cannabis use and symptom experience amongst people with mental illness: a commentary on Degenhardt et al. Psychol. Med. 2007, 37:913-916.
213. Maj P.F., Collu M., Fadda P., Cattaneo A., Racagni G., Riva M.A. Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptor 1 receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1- naphthalenylmethanone. Eur. J. Neurosci. 2007, 25:3305-3311.
214. Margolese H., Malchy L., Negrete J., Tempier R., Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr. Res. 2004, 67:157-166.
215. Marks D.F., MacAvoy M.G. Divided attention performance in cannabis users and non-users following alcohol and cannabis separately and in combination. Psychopharmacology 1989, 99:397-401.
216. Marriott K.S., Huffman J.W. Recent advances in the development of selective ligands for the cannabinoid CB(2) receptor. Curr. Top. Med. Chem. 2008, 8:187-204.
217. Marshall C. The active principle of Indian help; a preliminary communication. Lancet 1897, 1:235-238.
218. Mata I., Perez-Iglesias R., Roiz-Santianez R., Tordesillas-Gutierrez D., Pazos A., Gutierrez A., Vazquez-Barquero J.L., Crespo-Facorro B. Gyrification brain abnormalities associated with adolescence and early-adulthood cannabis use. Brain Res. 2010, 1317:297-304.
219. Mathew R.J., Wilson W.H., Turkington T.G., Coleman R.E. Cerebellar activity and disturbed time sense after THC. Brain Res. 1998, 797:183-189.
220. Matochik J.A., Eldreth D.A., Cadet J.L., Bolla K.I. Altered brain tissue composition in heavy marijuana users. Drug Alcohol Depend. 2005, 77:23-30.
221. Mayor's Committee on Marijuana The LaGuardia Committee Report: The Marihuana Problem in the City of New York 1944, The New York Academy of Medicine, New York.
222. McClure G.Y., McMillan D.E. Effects of drugs on response duration differentiation. VI: differential effects under differential reinforcement of low rates of responding schedules. J. Pharmacol. Exp. Ther. 1997, 281:1368-1380.
223. McCreadie R.G. Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br. J. Psychiatry 2002, 181:321-325.
224. McDonald J., Schleifer L., Richards J.B., de Wit H. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 2003, 28:1356-1365.
225. McGrath J., Welham J., Scott J., Varghese D., Degenhardt L., Hayatbakhsh M.R., Alati R., Williams G.M., Bor W., Najman J.M. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch. Gen. Psychiatry 2010, 67:440-447.
226. McGuire P.K., Jones P., Harvey I., Bebbington P., Toone B., Lewis S., Murray R.M. Cannabis and acute psychosis. Schizophr. Res. 1994, 13:161-167.
227. Medina K.L., Hanson K.L., Schweinsburg A.D., Cohen-Zion M., Nagel B.J., Tapert S.F. Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. J. Int. Neuropsychol. Soc. 2007, 13:807-820.
228. Medina K.L., Nagel B.J., Park A., McQueeny T., Tapert S.F. Depressive symptoms in adolescents: associations with white matter volume and marijuana use. J. Child Psychol. Psychiatry 2007, 48:592-600.
229. Medina K.L., Schweinsburg A.D., Cohen-Zion M., Nagel B.J., Tapert S.F. Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry. Neurotoxicol. Teratol. 2007, 29:141-152.
230. Meijer J.H., Dekker N., Koeter M.W., Quee P.J., van Beveren N.J., Meijer C.J. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. Psychol. Med. 2011, 1-12.
231. Melges F.T., Tinklenberg J.R., Hollister L.E., Gillespie H.K. Marihuana and temporal disintegration. Science 1970, 168:1118-1120.
232. Miller L.L., McFarland D., Cornett T.L., Brightwell D. Marijuana and memory impairment: effect on free recall and recognition memory. Pharmacol. Biochem. Behav. 1977, 7:99-103.
233. Millman R.B., Sbriglio R. Patterns of use and psychopathology in chronic marijuana users. Psychiatr. Clin. North Am. 1986, 9:533-545.
234. Mir A., Obafemi A., Young A., Kane C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 2011, 128:e1622-e1627.
235. Mirken B., Earleywine M. The cannabis and psychosis connection questioned: a comment on Fergusson et al. 2005. Addiction 2005, 100:714-715. author reply 715-716.
236. Molina-Holgado F., Alvarez F.J., Gonzalez I., Antonio M.T., Leret M.L. Maternal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) alters indolamine levels and turnover in adult male and female rat brain regions. Brain Res. Bull. 1997, 43:173-178.
237. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
238. Moreau J. Hashish and Mental Illness 1973, Raven, New York.
239. Morrison P.D., Zois V., McKeown D.A., Lee T.D., Holt D.W., Powell J.F., Kapur S., Murray R.M. The acute effects of synthetic intravenous delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol. Med. 2009, 39:1607-1616.
240. Morrison P.D., Nottage J., Stone J.M., Bhattacharyya S., Tunstall N., Brenneisen R., Holt D., Wilson D., Sumich A., McGuire P., Murray R.M., Kapur S., Ffytche D.H. Disruption of frontal theta coherence by delta9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology 2011, 36:827-836.
241. Mueser K., Bellack A., Blanchard J. Comorbidity of schizophrenia and substance abuse: implications for treatment. J. Consult. Clin. Psychol. 1992, 60:845-856.
242. Mulder J., Aguado T., Keimpema E., Barabas K., Ballester Rosado C.J., Nguyen L., Monory K., Marsicano G., Di Marzo V., Hurd Y.L., Guillemot F., Mackie K., Lutz B., Guzman M., Lu H.C., Galve-Roperh I., Harkany T. Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proc. Natl. Acad. Sci. U.S.A 2008, 105:8760-8765.
243. Muller H., Huttner H.B., Kohrmann M., Wielopolski J.E., Kornhuber J., Sperling W. Panic attack after spice abuse in a patient with ADHD. Pharmacopsychiatry 2010, 43:152-153.
244. Muller H., Sperling W., Kohrmann M., Huttner H.B., Kornhuber J., Maler J.M. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr. Res. 2010, 118:309-310.
245. Naatanen R., Alho K. Generators of electrical and magnetic mismatch responses in humans. Brain Topogr. 1995, 7:315-320.
246. Naatanen R., Kahkonen S. Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review. Int. J. Neuropsychopharmacol. 2009, 12:125-135.
247. Naatanen R., Picton T. The N1 wave of the human electric and magnetic response to sound: a review and an analysis of the component structure. Psychophysiology 1987, 24:375-425.
248. Nahas G.G. Hashish in Islam Ninth to Eighteenth century. Bull. N. Y. Acad. Med. 1982, 58:814-831.
249. Negrete J.C. Cannabis and schizophrenia. Br. J. Addict. 1989, 84:349-351.
250. Negrete J.C., Knapp W.P., Douglas D.E., Smith W.B. Cannabis affects the severity of schizophrenic symptoms: results of a clinical survey. Psychol. Med. 1986, 16:515-520.
251. News F. Fake Weed, Real Drug: K2 Causing Hallucinations in Teens (Fox News) 2011.
252. NIDA Info Facts: Spice 2011.
253. NPR Friend Says On 911 Call Demi Moore Was Convulsing (NPR) 2011.
254. O'Donnell B.F., Vohs J.L., Hetrick W.P., Carroll C.A., Shekhar A. Auditory event-related potential abnormalities in bipolar disorder and schizophrenia. Int. J. Psychophysiol. 2004, 53:45-55.
255. O'Shea M., Singh M.E., McGregor I.S., Mallet P.E. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J. Psychopharmacol. 2004, 18:502-508.
256. Oudin M.J., Gajendra S., Williams G., Hobbs C., Lalli G., Doherty P. Endocannabinoids regulate the migration of subventricular zone-derived neuroblasts in the postnatal brain. J. Neurosci. 2011, 31:4000-4011.
257. Patrick G., Struve F.A. Reduction of auditory P50 gating response in marihuana users: further supporting data. Clin. Electroencephalogr. 2000, 31:88-93.
258. Patrick G., Straumanis J.J., Struve F.A., Fitz-Gerald M.J., Leavitt J., Manno J.E. Reduced P50 auditory gating response in psychiatrically normal chronic marihuana users: a pilot study. Biol. Psychiatry 1999, 45:1307-1312.
259. Patterson J.V., Hetrick W.P., Boutros N.N., Jin Y., Sandman C., Stern H., Potkin S., Bunney W.E. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res. 2008, 158:226-247.
260. Peralta V., Cuesta M.J. Influence of cannabis abuse on schizophrenic psychopathology. Acta Psychiatr. Scand. 1992, 85:127-130.
261. Peters B., de Koning P., Dingemans P., Becker H., Linszen D., de Haan L. Subjective effects of cannabis before the first psychotic episode. Aust. N. Z. J. Psychiatry 2009, 43:1155-1162.
262. Peters B.D., de Haan L., Vlieger E.J., Majoie C.B., den Heeten G.J., Linszen D.H. Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity?. Psychopharmacol. Bull. 2009, 42:75-88.
263. Picton T.W., Hillyard S.A., Krausz H.I., Galambos R. Human auditory evoked potentials. I. Evaluation of components. Electroencephalogr. Clin. Neurophysiol. 1974, 36:179-190.
264. Polich J., Corey-Bloom J. Alzheimer's disease and P300: review and evaluation of task and modality. Curr. Alzheimer Res. 2005, 2:515-525.
265. Polich J., Criado J.R. Neuropsychology and neuropharmacology of P3a and P3b. Int. J. Psychophysiol. 2006, 60:172-185.
266. Polich J., Pollock V.E., Bloom F.E. Meta-analysis of P300 amplitude from males at risk for alcoholism. Psychol. Bull. 1994, 115:55-73.
267. Pope H.G. Cannabis, cognition, and residual confounding. JAMA 2002, 287:1172-1174.
268. Pope H.G., Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996, 275:521-527.
269. Pope H.G., Gruber A.J., Yurgelun-Todd D. The residual neuropsychological effects of cannabis: the current status of research. Drug Alcohol Depend. 1995, 38:25-34.
270. Pope H.G., Gruber A.J., Hudson J.I., Huestis M.A., Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch. Gen. Psychiatry 2001, 58:909-915.
271. Pope H.G., Gruber A.J., Yurgelun-Todd D. Residual neuropsychologic effects of cannabis. Curr. Psychiatry Rep. 2001, 3:507-512.
272. Pope H.G., Gruber A.J., Hudson J.I., Huestis M.A., Yurgelun-Todd D. Cognitive measures in long-term cannabis users. J. Clin. Pharmacol. 2002, 42:41S-47S.
273. Pope H.G., Gruber A.J., Hudson J.I., Cohane G., Huestis M.A., Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association?. Drug Alcohol Depend. 2003, 69:303-310.
274. Post W. The Growing Buzz on 'Spice' - the Marijuana Alternative (Washington Post) 2011.
275. Potter D., Summerfelt A., Gold J., Buchanan R.W. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr. Bull. 2006, 32:692-700.
276. Potvin S., Briand C., Prouteau A., Bouchard R.H., Lipp O., Lalonde P., Nicole L., Lesage A., Stip E. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn. 2005, 59:38-42.
277. Potvin S., Mancini-Marie A., Fahim C., Mensour B., Levesque J., Karama S., Beauregard M., Rompre P.P., Stip E. Increased striatal gray matter densities in patients with schizophrenia and substance use disorder: a voxel-based morphometry study. Psychiatry Res. 2007, 154:275-279.
278. Potvin S., Joyal C.C., Pelletier J., Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr. Res. 2008, 100:242-251.
279. Psychoyos D., Hungund B., Cooper T., Finnell R.H. A cannabinoid analogue of delta9-tetrahydrocannabinol disrupts neural development in chick. Birth Defects Res. B Dev. Reprod. Toxicol. 2008, 83:477-488.
280. Psychoyos D., Vinod K.Y., Cao J., Xie S., Hyson R.L., Wlodarczyk B., He W., Cooper T.B., Hungund B.L., Finnell R.H. Cannabinoid receptor 1 signaling in embryo neurodevelopment. Birth Defects Res. B Dev. Reprod. Toxicol 2012.
281. Quinn H.R., Matsumoto I., Callaghan P.D., Long L.E., Arnold J.C., Gunasekaran N., Thompson M.R., Dawson B., Mallet P.E., Kashem M.A., Matsuda-Matsumoto H., Iwazaki T., McGregor I.S. Adolescent rats find repeated delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 2008, 33:1113-1126.
282. Rabin R.A., Zakzanis K.K., George T.P. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr. Res. 2011, 128:111-116.
283. Rais M., Cahn W., Van Haren N., Schnack H., Caspers E., Hulshoff Pol H., Kahn R. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am. J. Psychiatry 2008, 165:490-496.
284. Ranganathan M., D'Souza D.C. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl.) 2006, 188:425-444.
285. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 2005, 10:434-449.
286. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA 1990, 264:2511-2518.
287. Reilly D., Didcott P., Swift W., Hall W. Long-term cannabis use: characteristics of users in an Australian rural area. Addiction 1998, 93:837-846.
288. Renault P.F., Schuster C.R., Heinrich R., Freeman D.X. Marihuana: standardized smoke administration and dose effect curves on heart rate in humans. Science 1971, 174:589-591.
289. Renault P.F., Schuster C.R., Freedman D.X., Sikic B., de Mello D.N. Repeat administration of marihuana smoke to humans. Arch. Gen. Psychiatry 1974, 31:95-102.
290. Rentzsch J., Penzhorn A., Kernbichler K., Plockl D., Gomez-Carrillo de Castro A., Gallinat J., Jockers-Scherubl M.C. Differential impact of heavy cannabis use on sensory gating in schizophrenic patients and otherwise healthy controls. Exp. Neurol. 2007, 205:241-249.
291. Ringen P.A., Vaskinn A., Sundet K., Engh J.A., Jonsdottir H., Simonsen C., Friis S., Opjordsmoen S., Melle I., Andreassen O.A. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychol. Med. 2010, 40:1337-1347.
292. Rinne T., Alho K., Ilmoniemi R.J., Virtanen J., Naatanen R. Separate time behaviors of the temporal and frontal mismatch negativity sources. NeuroImage 2000, 12:14-19.
293. Rissling A.J., Makeig S., Braff D.L., Light G.A. Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr. Psychiatry Rep. 2010, 12:572-578.
294. Rosburg T., Boutros N.N., Ford J.M. Reduced auditory evoked potential component N100 in schizophrenia-a critical review. Psychiatry Res. 2008, 161:259-274.
295. Roser P., Della B., Norra C., Uhl I., Brune M., Juckel G. Auditory mismatch negativity deficits in long-term heavy cannabis users. Eur. Arch. Psychiatry Clin. Neurosci 2008.
296. Roth W.T., Cannon E.H. Some features of the auditory evoked response in schizophrenics. Arch. Gen. Psychiatry 1972, 27:466-471.
297. RTL Synthetic Cannabinoid Urine Test 2012.
298. Rubino T., Vigano D., Premoli F., Castiglioni C., Bianchessi S., Zippel R., Parolaro D. Changes in the expression of G protein-coupled receptor kinases and beta-arrestins in mouse brain during cannabinoid tolerance: a role for RAS-ERK cascade. Mol. Neurobiol. 2006, 33:199-213.
299. Rubino T., Realini N., Braida D., Guidi S., Capurro V., Vigano D., Guidali C., Pinter M., Sala M., Bartesaghi R., Parolaro D. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 2009, 19:763-772.
300. Saletu B., Itil T.M., Saletu M. Auditory evoked response, EEG, and thought process in schizophrenics. Am. J. Psychiatry 1971, 128:336-344.
301. Scallet A.C. Neurotoxicology of cannabis and THC: a review of chronic exposure studies in animals. Pharmacol. Biochem. Behav. 1991, 40:671-676.
302. Scallet A.C., Uemura E., Andrews A., Ali S.F., McMillan D.E., Paule M.G., Brown R.M., Slikker W. Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res. 1987, 436:193-198.
303. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict. Biol. 2008, 13:253-263.
304. Schneider M., Schomig E., Leweke F.M. Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict. Biol. 2008, 13:345-357.
305. Schneir A.B., Cullen J., Ly B.T. "Spice" girls: synthetic cannabinoid intoxication. J. Emerg. Med. 2011, 40:296-299.
306. Schofield D., Tennant C., Nash L., Degenhardt L., Cornish A., Hobbs C., Brennan G. Reasons for cannabis use in psychosis. Aust. N. Z. J. Psychiatry 2006, 40:570-574.
307. Scholes K.E., Martin-Iverson M.T. Cannabis use and neuropsychological performance in healthy individuals and patients with schizophrenia. Psychol. Med. 2010, 40:1635-1646.
308. Schulze G.E., McMillan D.E., Bailey J.R., Scallet A., Ali S.F., Slikker W., Paule M.G. Acute effects of delta-9-tetrahydrocannabinol in rhesus monkeys as measured by performance in a battery of complex operant tests. J. Pharmacol. Exp. Ther. 1988, 245:178-186.
309. Semple D.M., Ramsden F., McIntosh A.M. Reduced binocular depth inversion in regular cannabis users. Pharmacol. Biochem. Behav. 2003, 75:789-793.
310. 9-THC 3 April 2011.
311. Sewell R.A., Ranganathan M., D'Souza D.C. Cannabinoids and psychosis. Int. Rev. Psychiatry 2009, 21:152-162.
312. Sheidler V.R., Ettinger D.S., Diasio R.B., Enterline J.P., Brown M.D. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. J. Clin. Pharmacol. 1984, 24:155-159.
313. Siler J.F., Sheep W.L., Bates L.B., Clark G.F., Cook G.W., Smith W.A. Marihuana smoking in Panama. Mil. Surg. 1933, 73:269-280.
314. Singh S.M., Basu D. The P300 event-related potential and its possible role as an endophenotype for studying substance use disorders: a review. Addict. Biol. 2009, 14:298-309.
315. Skosnik P.D., Krishnan G.P., Vohs J.L., O'Donnell B.F. The effect of cannabis use and gender on the visual steady state evoked potential. Clin. Neurophysiol. 2006, 117:144-156.
316. Skosnik P.D., Edwards C.R., O'Donnell B.F., Steffen A., Steinmetz J.E., Hetrick W.P. Cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar-dependent learning. Neuropsychopharmacology 2008, 33:1432-1440.
317. Skosnik P.D., Park S., Dobbs L., Gardner W.L. Affect processing and positive syndrome schizotypy in cannabis users. Psychiatry Res. 2008, 157:279-282.
318. Smith D.E. Acute and chronic toxicity of marijuana. J. Psychedelic Drugs 1968, 2:37-47.
319. Solowij N. Do cognitive impairments recover following cessation of cannabis use?. Life Sci. 1995, 56:2119-2126.
320. Solowij N., Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr. Drug Abuse Rev. 2008, 1:81-98.
321. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. J. Psychiatry Neurosci. 2007, 32:30-52.
322. Solowij N., Michie P.T., Fox A.M. Effects of long-term cannabis use on selective attention: an event-related potential study. Pharmacol. Biochem. Behav. 1991, 40:683-688.
323. Solowij N., Michie P.T., Fox A.M. Differential impairments of selective attention due to frequency and duration of cannabis use. Biol. Psychiatry 1995, 37:731-739.
324. Solowij N., Yucel M., Respondek C., Whittle S., Lindsay E., Pantelis C., Lubman D.I. Cerebellar white-matter changes in cannabis users with and without schizophrenia. Psychol. Med. 2011, 41:2349-2359.
325. Spencer D.J. Cannabis-induced psychosis. Int. J. Addict. 1971, 6:323-326.
326. Spencer C., Castle D., Michie P.T. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr. Bull. 2002, 28:233-247.
327. Stambaugh J.E., McAdams J., Vreeland F. Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. J. Clin. Pharmacol. 1984, 24:480-485.
328. Stirling J., Lewis S., Hopkins R., White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 2005, 75:135-137.
329. Stone J.M., Morrison P.D., Nottage J., Bhattacharyya S., Feilding A., McGuire P.K. Delta-9-tetrahydrocannabinol disruption of time perception and of self-timed actions. Pharmacopsychiatry 2010, 43:236-237.
330. Struve F.A., Straumanis J.J. Electroencephalographic and evoked-potential methods in human marijuana research - historical review and future-trends. Drug Dev. Res. 1990, 20:369-388.
331. Stuart-Harris R.C., Mooney C.A., Smith I.E. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy. Clin. Oncol. 1983, 9:143-146.
332. Suckling J. Correlated covariates in ANCOVA cannot adjust for pre-existing differences between groups. Schizophr. Res. 2011, 126:310-311.
333. Swartz M., Wagner H., Swanson J., Stroup T., McEvoy J., Canive J., Miller D., Reimherr F., McGee M., Khan A., Van Dorn R., Rosenheck R., Lieberman J. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J. Nerv. Ment. Dis. 2006, 194:164-172.
334. Swartz M.S., Stroup T.S., McEvoy J.P., Davis S.M., Rosenheck R.A., Keefe R.S., Hsiao J.K., Lieberman J.A. What CATIE found: results from the schizophrenia trial. Psychiatr. Serv. 2008, 59:500-506. Washington, D.C.
335. Szeszko P.R., Robinson D.G., Sevy S., Kumra S., Rupp C.I., Betensky J.D., Lencz T., Ashtari M., Kane J.M., Malhotra A.K., Gunduz-Bruce H., Napolitano B., Bilder R.M. Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br. J. Psychiatry 2007, 190:230-236.
336. Talbott J.A., Teague J.W. Marihuana psychosis. Acute toxic psychosis associated with the use of cannabis derivatives. JAMA 1969, 210:299-302.
337. Tennant F.S., Groesbeck C.J. Psychiatric effects of hashish. Arch. Gen. Psychiatry 1972, 27:133-136.
338. Test M.A., Wallisch L.S., Allness D.J., Ripp K. Substance use in young adults with schizophrenic disorders. Schizophr. Bull. 1989, 15:465-476.
339. Thacore V.R. Bhang psychosis. Br. J. Psychiatry 1973, 123:225-229.
340. Thaker G.K. Neurophysiological endophenotypes across bipolar and schizophrenia psychosis. Schizophr. Bull. 2008, 34:760-773.
341. Tinklenberg J.R., Kopell B.S., Melges F.T., Hollister L.E. Marihuana and alcohol, time production and memory functions. Arch. Gen. Psychiatry 1972, 27:812-815.
342. Today U. 'Spice' makers change recipes to sidestep bans 2011.
343. Tramer M.R., Carroll D., Campbell F.A., Reynolds D.J., Moore R.A., McQuay H.J. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001, 323:16-21.
344. Treffert D.A. Marijuana use in schizophrenia: a clear hazard. Am. J. Psychiatry 1978, 135:1213-1215.
345. Turetsky B.I., Colbath E.A., Gur R.E. P300 subcomponent abnormalities in schizophrenia: I. Physiological evidence for gender and subtype specific differences in regional pathology. Biol. Psychiatry 1998, 43:84-96.
346. Turetsky B.I., Calkins M.E., Light G.A., Olincy A., Radant A.D., Swerdlow N.R. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr. Bull. 2007, 33:69-94.
347. Turetsky B.I., Greenwood T.A., Olincy A., Radant A.D., Braff D.L., Cadenhead K.S., Dobie D.J., Freedman R., Green M.F., Gur R.E., Gur R.C., Light G.A., Mintz J., Nuechterlein K.H., Schork N.J., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Calkins M.E. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol. Psychiatry 2008, 64:1051-1059.
348. Tysk L. Time estimation by healthy subjects and schizophrenic patients: a methodological study. Percept. Mot. Skills 1983, 56:983-988.
349. Tzilos G.K., Cintron C.B., Wood J.B., Simpson N.S., Young A.D., Pope H.G., Yurgelun-Todd D.A. Lack of hippocampal volume change in long-term heavy cannabis users. Am. J. Addict. 2005, 14:64-72.
350. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Haishima Y., Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem. Pharm. Bull. 2009, 57:439-441.
351. Uchiyama N., Kikura-Hanajiri R., Ogata J., Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci. Int. 2010, 198:31-38.
352. Uchiyama N., Kikura-Hanajiri R., Goda Y. Identification of a novel cannabimimetic phenylacetylindole, cannabipiperidiethanone, as a designer drug in a herbal product and its affinity for cannabinoid CB and CB receptors. Chem. Pharm. Bull. 2011, 59:1203-1205.
353. Umbricht D., Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr. Res. 2005, 76:1-23.
354. Umbricht D., Koller R., Schmid L., Skrabo A., Grubel C., Huber T., Stassen H. How specific are deficits in mismatch negativity generation to schizophrenia?. Biol. Psychiatry 2003, 53:1120-1131.
355. Valjent E., Pages C., Rogard M., Besson M.J., Maldonado R., Caboche J. Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. Eur. J. Neurosci. 2001, 14:342-352.
356. van Dijk D., Koeter M.W., Hijman R., Kahn R.S., van den Brink W. Effect of cannabis use on the course of schizophrenia in male patients: aprospective cohort study. Schizophr. Res 2012.
357. Van Mastrigt S., Addington J., Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol. 2004, 39:69-72.
358. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002, 156:319-327.
359. Vandrey R., Dunn K.E., Fry J.A., Girling E.R. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug Alcohol Depend. 2012, 120:238-241.
360. Vearrier D., Osterhoudt K.C. A teenager with agitation: higher than she should have climbed. Pediatr. Emerg. Care. 2010, 26:462-465.
361. Veen N.D., Selten J.P., van der Tweel I., Feller W.G., Hoek H.W., Kahn R.S. Cannabis use and age at onset of schizophrenia. Am. J. Psychiatry 2004, 161:501-506.
362. Verdejo-Garcia A.J., Lopez-Torrecillas F., Aguilar de Arcos F., Perez-Garcia M. Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis. Addict. Behav. 2005, 30:89-101.
363. Verdejo-Garcia A., Bechara A., Recknor E.C., Perez-Garcia M. Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction. J. Int. Neuropsychol. Soc. 2006, 12:405-415.
364. Volkow N., Fowler J., Wolf A., Gillespi H. Metabolic studies of drugs of abuse 1991, 47-53. National Institute of Drug Abuse, Report no. 105. M.D. Bethesda (Ed.).
365. Wang X., Dow-Edwards D., Anderson V., Minkoff H., Hurd Y.L. In utero marijuana exposure associated with abnormal amygdala dopamine D2 gene expression in the human fetus. Biol. Psychiatry 2004, 56:909-915.
366. Warner R., Taylor D., Wright J., Sloat A., Springett G., Arnold S., Weinberg H. Substance use among the mentally ill: prevalence, reasons for use, and effects on illness. Am. J. Orthopsychiatry 1994, 64:30-39.
367. Warnock J. Insanity from hasheesh. J. Ment. Sci. 1903, 49:96-110.
368. Watson S., Chambers D., Hobbs C., Doherty P., Graham A. The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation. Mol. Cell. Neurosci. 2008, 38:89-97.
369. Weil A.T. Adverse reactions to marihuana. Classification and suggested treatment. N. Engl. J. Med. 1970, 282:997-1000.
370. Weil A.T., Zinberg N.E., Nelsen J.M. Clinical and psychological effects of marihuana in man. Science 1968, 162:1234-1242.
371. Weinberger D.R. On the plausibility of "the neurodevelopmental hypothesis" of schizophrenia. Neuropsychopharmacology 1996, 14:1S-11S.
372. Weiser M., Knobler H.Y., Noy S., Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am. J. Med. Genet. 2002, 114:949-955.
373. Wesnes K., Annas P., Edgar C., Deeprose C., Karlsten R., Philipp A., Kalliomaki J., Segerdahl M. Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. J. Psychopharmacol. (Oxford, England) 2009.
374. Wilk J., Marcus S.C., West J., Countis L., Hall R., Regier D.A., Olfson M. Substance abuse and the management of medication nonadherence in schizophrenia. J. Nerv. Ment. Dis. 2006, 194:454-457.
375. Williams E.H., Himmelsbach C.K., Lloyd B.J., Ruble D.C., Wikler A. Studies on marihuana and parahexyl compound. Public Health Rep. 1946, 61:1059-1083.
376. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
377. Wilson W., Mathew R., Turkington T., Hawk T., Coleman R.E., Provenzale J. Brain morphological changes and early marijuana use: a magnetic resonance and positron emission tomography study. J. Addict. Dis. 2000, 19:1-22.
378. Wobrock T., Sittinger H., Behrendt B., D'Amelio R., Falkai P. Comorbid substance abuse and brain morphology in recent-onset psychosis. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259:28-36.
379. Yucel M., Solowij N., Respondek C., Whittle S., Fornito A., Pantelis C., Lubman D.I. Regional brain abnormalities associated with long-term heavy cannabis use. Arch. Gen. Psychiatry 2008, 65:694-701.
380. Yucel M., Bora E., Lubman D.I., Solowij N., Brewer W.J., Cotton S.M., Conus P., Takagi M.J., Fornito A., Wood S.J., McGorry P.D., Pantelis C. The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr. Bull. 2012, 38:316-330.
381. Zachariou M., Dissanayake D.W., Coombes S., Owen M.R., Mason R. Sensory gating and its modulation by cannabinoids: electrophysiological, computational and mathematical analysis. Cogn. Neurodyn. 2008, 2:159-170.
382. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002, 325:1199.
383. Zisook S., Heaton R., Moranville J., Kuck J., Jernigan T., Braff D. Past substance abuse and clinical course of schizophrenia. Am. J. Psychiatry 1992, 149:552-553.
384. Zuardi A.W., Rodrigues J.A., Cunha J.M. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl.) 1991, 104:260-264.
385. Zuardi A.W., Morais S.L., Guimaraes F.S., Mechoulam R. Antipsychotic effect of cannabidiol. J. Clin. Psychiatry 1995, 56:485-486.
386. Zuardi A.W., Crippa J.A., Hallak J.E., Moreira F.A., Guimaraes F.S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res. 2006, 39:421-429.
387. Zuardi A.W., Hallak J.E., Dursun S.M., Morais S.L., Sanches R.F., Musty R.E., Crippa J.A. Cannabidiol monotherapy for treatment-resistant schizophrenia. J. Psychopharmacol. 2006, 20:683-686.
388. Zuardi A.W., Crippa J.A., Hallak J.E., Pinto J.P., Chagas M.H., Rodrigues G.G., Dursun S.M., Tumas V. Cannabidiol for the treatment of psychosis in Parkinson's disease. J. Psychopharmacol. 2009, 23:979-983.